Ashwagandha derived withanone targets TPX2-Aurora A complex: computational and experimental evidence to its anticancer activity
Grover A, Singh R, Shandilya A, Priyandoko D, Agrawal V, Bisaria VS, Wadhwa R, Kaul SC, Sundar D
PloS one · 36 citas
Etiquetas de revisión
Solo mecanismosDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Estudio in vitro o de mecanismos (clasificado por nuestro filtro de IA)
- Estudiado en
- Células o muestras de laboratorio
- Resultado principal
- Solo mecanismos
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Institute of Advanced Industrial Science and Technology
- Gobierno
- Ministry of Education, Culture, Sports, Science and Technology
- Universidad u hospital
- Indian Institute of Technology Delhi
Según 3 financiadores declarados.
Publicación
- Publicado
- 2012-01-27 · PLoS One · vol. 7 · número 1 · pág. e30890
- Editorial
- Public Library of Science
- Citado
- 58 citas · más que el 87% de estudios similares · 2.3× el promedio de su campo
- Referencias
- 57 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Microtubule and mitosis dynamics · Cancer-related Molecular Pathways · Protein Kinase Regulation and GTPase Signaling
- Palabras clave
- Aurora kinase, Cytokinesis, Mitosis, Kinase, Aurora B kinase, Aurora A kinase, Aurora inhibitor, Cell biology, Biology, Cancer cell, Docking (animal), Cell cycle, Cancer, Cell division, Cell, Biochemistry, Genetics, Medicine
- MeSH
- cell line, tumor, humans, withania, triterpenes, cell cycle proteins, microtubule-associated proteins, nuclear proteins, rna, messenger, plant extracts, antineoplastic agents, biological assay, drug screening assays, antitumor, cluster analysis, reproducibility of results, reverse transcriptase polymerase chain reaction, gene expression regulation, enzymologic, female, withanolides, molecular dynamics simulation, aurora kinases, protein serine-threonine kinases
9 autores
- Abhinav Grover🇮🇳Indian Institute of Technology Delhi
- Rumani Singh🇯🇵University of Tsukuba; National Institute of Advanced Industrial Science and Technology
- Ashutosh Shandilya🇮🇳Indian Institute of Technology Delhi
- Didik Priyandoko🇯🇵University of Tsukuba; National Institute of Advanced Industrial Science and Technology
- Vibhuti Agrawal🇮🇳Indian Institute of Technology Delhi
- Virendra Swarup Bisaria🇮🇳Indian Institute of Technology Delhi
- Renu Wadhwa🇯🇵National Institute of Advanced Industrial Science and Technology
- Sunil C. Kaul🇯🇵 · autor de correspondenciaNational Institute of Advanced Industrial Science and Technology
- Durai Sundar🇮🇳 · autor de correspondenciaIndian Institute of Technology Delhi
Resumen
El texto original del estudio, en el idioma en que se publicó.
Cancer is largely marked by genetic instability. Specific inhibition of individual proteins or signalling pathways that regulate genetic stability during cell division thus hold a great potential for cancer therapy. The Aurora A kinase is a Ser/Thr kinase that plays a critical role during mitosis and cytokinesis and is found upregulated in several cancer types. It is functionally regulated by its interactions with TPX2, a candidate oncogene. Aurora A inhibitors have been proposed as anticancer drugs that work by blocking its ATP binding site. This site is common to other kinases and hence these inhibitors lack specificity for Aurora A inhibition in particular, thus advocating the need of some alternative inhibition route. Previously, we identified TPX2 as a cellular target for withanone that selectively kill cancer cells. By computational approach, we found here that withanone binds to TPX2-Aurora A complex. In experiment, withanone treatment to cancer cells indeed resulted in dissociation of TPX2-Aurora A complex and disruption of mitotic spindle apparatus proposing this as a mechanism of the anticancer activity of withanone. From docking analysis, non-formation/disruption of the active TPX2-Aurora A association complex could be discerned. Our MD simulation results suggesting the thermodynamic and structural stability of TPX2-Aurora A in complex with withanone further substantiates the binding. We report a computational rationale of the ability of naturally occurring withanone to alter the kinase signalling pathway in an ATP-independent manner and experimental evidence in which withanone cause inactivation of the TPX2-Aurora A complex. The study demonstrated that TPX2-Aurora A complex is a target of withanone, a potential natural anticancer drug.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.